What type of drug is Alectinib?
Alectinib belongs to the group of medicines called antineoplastics (cancer medicines). It works by interfering with the growth of cancer cells, which are eventually destroyed. This product is available in the following dosage forms: Capsule.
What generation is Alectinib?
Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non-Small Cell Lung Cancer. J Adv Pract Oncol. Jan-Feb 2018;9(1):94-101.
Is Alectinib a monoclonal antibody?
Therapies that target receptors are also known as monoclonal antibodies. Antiangiogenesis inhibitors target the blood vessels that supply oxygen to the cells, ultimately causing the cells to starve. Alectinib is a targeted therapy. It is a tyrosine kinase inhibitor (TKI).
Where is Alectinib made?
Alectinib (INN, marketed as Alecensa) is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK) and is used to treat non-small-cell lung cancer (NSCLC). It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group.
How long can you take Alectinib?
by Drugs.com In the clinical trial ALEX: NCT02075840, the length of time Alecensa was taken ranged from months to over a year, with the median length of time being 18.6 months. Alecensa treatment usually continues until there is disease progression or the patient has unacceptable side effects.
How do ALK inhibitors work?
They fall under the category of tyrosine kinase inhibitors, which work by inhibiting proteins involved in the abnormal growth of tumour cells. All the current approved ALK inhibitors function by binding to the ATP pocket of the abnormal ALK protein, blocking its access to energy and deactivating it.
Does Tagrisso shrink tumors?
The study found: 77% of those taking TAGRISSO saw their brain tumors shrink. 18% saw their brain tumors completely disappear. 63% of those treated with other EGFR-targeted therapies, erlotinib or gefitinib, saw their brain tumors shrink.
What is an ALK gene?
ALK is short for anaplastic lymphoma kinase. It’s a mutation in the DNA of your lung cells that happens when two genes become fused, or stuck together. When you have this mutation, your lung cells make too many copies of themselves. These cells are cancerous and can spread to other parts of your body.
Is Alectinib an ALK inhibitor?
Alectinib is an ALK inhibitor—a targeted therapy that blocks the activity of mutated ALK proteins. About 5% of NSCLC tumors are ALK positive.
What is the mechanism of action of alectinib?
Alectinib is a Kinase Inhibitor. The mechanism of action of alectinib is as a Kinase Inhibitor. Alectinib is an orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity.
How do you make alectinib hydrochloride?
Alectinib hydrochloride is a hydrochloride obtained by combining alectinib with one molar equivalent of hydrochloric acid. Used for the treatment of patients with anaplastic lymphoma kinase-positive, metastatic non-small cell lung cancer.
Is alectinib a substrate for P-gp?
In vitro studies suggest that alectinib is not a substrate for P-gp while M4 is. The mean elimination half life is 33 hr for alectinib and 31 hr for M4. Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase.
Who is the manufacturer of alectinib?
It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group. Alectinib was approved in Japan in July 2014 for the treatment of ALK fusion-gene positive, unresectable, advanced or recurrent non-small-cell lung cancer (NSCLC).